

CORRIGENDUM

Corrigendum: First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor

Vidya Perera, Zhaoqing Wang, Joseph Luetzgen, Danshi Li, Mary DeSouza, Michael Cerra, Dietmar Seiffert, *Clin Transl Sci.* 2022;15:330–342. <https://doi.org/10.1111/cts.13148>

In the published version of the above article, the authors would like to add the following to the Acknowledgments section:

The authors wish to thank Robert Frost, M.D. Ph.D. and Cesare Russo, M.D. for their early contributions to this study.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *Clinical and Translational Science* published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.